camurus_®

Annual General Meting 2025

CEO presentation 27 May 2025



Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Camurus snapshot



Rapidly growing commercial stage company

Leader in opioid dependence treatment with Buvidal[®] and Brixadi[®] weekly and monthly depots



Unique FluidCrystal[®] technology platform

Commercially validated with a broad range of applications



Advancing late-stage pipeline with blockbuster potential

Prospect for multiple new approvals in rare disease and oncology indications



Strong operational and financial performance

Sustainable profitability since 2022



Listed on Nasdaq Stockholm Ticker **CAMX;** Employees: **275+**



Successful 2024 for Camurus

- Strong financial development and high profitability
- S Global leadership in opioid dependence treatment
- High growth of Buvidal[®] and Brixadi[®]
- Registration applications for CAM2029 in acromegaly and advancing studies in GEP-NET and PLD
- Initiation of clinical study of monthly semaglutide (CAM2056)
- Strengthened sustainability work and improved ESG rankings







Positive financial development

MSEK 600 400 200 -200 -200 -207 -112 -112 -112 -112 -207 -112 -207 -112 -207 -112 -207 -112 -202 2022 2023 2024

Profit before tax

One-time revenue related to Brixadi US approval
 Revenues excl. one-times for Brixadi US approval

One-time revenue related to Brixadi US approval
 Profit before tax excl. Brixadi US approval revenue





Strategy for continued value creation

- Grow Buvidal/Brixadi sales and expand to new markets
 Advance R&D pipeline to new approvals and launches
 Diversify and grow through business development
 - Drive operational excellence and sustainable profitability

Camurus' vision 2027

Sustainable value creation for all stakeholders:



Five-fold revenue growth (to SEK 4.5 billion)



Establishment of US commercial infrastructure



pipeline

programs

~50%

camurus

Operating margin around 50%

On track towards Camurus vision 2027

CAM2029 NET and PLD

Status after 2 of 5 years – end-2024



- Commercial preparations for ✓ US launch in September 2023
- □ >\$1 billion peak sales potential

Updated NDA in the US


CAM2029 GEP-NET and PLD

- ✓ POSITANO and SORENTO advancing
- Results POSITANO in O2


Commercially validated FluidCrystal® technology

- Seasy and convenient administration
- Rapid onset & long-acting release
- Sor peptide and small molecule drugs

- Compatible with prefilled syringes and auto-injector pens
- Scalable manufacturing
- Strong and updated patent portfolio




Development of long-acting medications



- Less frequent dosing
- Sustained therapeutic exposure
- Improved treatment compliance
- Improved efficacy and/or reduced side effects
- More convenient treatment

Broad and diversified product portfolio and pipeline



Other clinical stage programs include CAM2032 (prostate cancer), CAM2043 (PAH³), and CAM2047 (CINV⁴)



Buvidal – game changing opioid dependence treatment

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over¹

Buvidal has demonstrated significant benefits to patients and society

- Superior treatment outcome and patient satisfaction¹⁻⁴
- Solution Blocks subjective opioid effects from first dose²
- Reduces treatment burden and improve quality of life^{4,5}
- Decrease risk of diversion, misuse and pediatric exposure^{6,7}
- Provides cost savings⁸

¹Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; ²Walsh et al, JAMA Psychiatry 2017;74(9):894-902; ³Frost, M., et al. Addiction. 2019;114(8):1416-1426. <u>doi: 10.1111/add.14636</u>; ⁴Lintzeris, N., et al. JAMA Network Open. 2021;4(5):e219041. <u>doi:10.1001/jamanetworkopen.2021.9041</u>, ⁵Barnett et al Drug and Alcohol Dependence 2021; <u>https://doi.org/10.1016/j.drugalcdep.2021.108959</u>; ⁶EPAR for Buvidal; ⁷Dunlop, A. J., et al. Addiction. 2021. <u>https://doi.org/10.1111/add.15627</u>; ⁸Dunlop, A. Oral presentation at CPDD June 2020.



Global leadership in long-acting treatment of opioid dependence


Improved access and market share

 Buvidal and Brixadi are global leading products in long-acting opioid dependence treatment¹

Strong growth in Europe, Australia and the MENA region

- Buvidal shown CAGR of 87% since first launch in 2019
- ~60,000 patients in treatment end-2024
- More than 80% market share of long-acting treatments in Australia and EU
- New price and reimbursement approvals in Ireland, Switzerland, Luxembourg and Portugal
- Goal: More than 100,000 patients in 2027

13




Product sales Buvidal

Successful launch of Brixadi in the US

Positive uptake in the US

- Launched in September 2023
- About 80% payer coverage after 6 months
- ~25% market share of long-acting segment after first full year on the market, end-2024^1
- Growth slowing down in Q1 2025
- Peak sales potential > \$1 billion²
 - Around 6-7 million people with opioid dependence in the US³⁻⁵
 - Approximately 2 million receiving medication assisted treatment⁶




Growing evidence base

- Increasing treatment difference between CAM2038 and daily standard treatment (SL BPN/NX) in patients with high illicit drug concentrations
- CAM2038 superior to daily standard treatment in patients using fentanyl
- Weekly buprenorphine well tolerated and safe in emergency care patients with minimal to low abstinence³
- Pharmacokinetic-dynamic model showing effective blockade of drug liking effects with CAM2038⁴
- Half of all patients in Australia receiving long-acting treatment – driven by high demand and reduced treatment burden and stigma

	JOURNAL OF Addiction Medicine The Official Journal of the American Society of Addiction Medicine
JAMA Open.	ORIGINAL RESEARCH Exploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial Peterson, Stefan PhD; Nunes, Edward V. MD; Lofwall, Michelle R. MD; Walsh, Sharon L. PhD; ⁽¹⁾ Tiberg, Fredrik PhD
Original Investigation Substance Use and Extended-Release Inject for Opioid Use Disorder \ A Post Hoc Analysis of a R	ion vs Sublingual Buprenorphine Nith Fentanyl Use
Edward V. Nunes. MD; Sandra D. Comer, PhD; Mich Fredrik Tiberg, PhD: Peter Hjelmstrom, MD, PhD; N	elle R. Lofi
	Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
www.nature.com/npp	Gail D'Ondrie, MD ^{23,4} , Andrew A. Henring, MM ^{5,A3} , Jaanmarke Perrone, MD ⁷ , <u>et al.</u> 3: Author Affiliations I. Article Information JAMA New Open, 2024;7(7):e8242002. doi:10.1001/jamanetworkopen.2024.20702
Peter Hjelmström @ ⁴⁵ and Fredrik Tiberg ⁴ © The Author(s) 2024	MJA The Medical Journal of Australia Australia's most trusted source of medical information
	Research letters 🕆 🙆 Open Access 🖉 💮
	The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019–2022: longitudinal sales data analysis
	Nicholas Lintzeris 🕵 Victoria Hayes, Adrian J Dunlop

First published: 04 March 2024 | https://doi.org/10.5694/mia2.52250

Patient benefits – Camurus' driving force



Octreotide SC depot, CAM2029

Under development for the treatment of three rare disease indications

S Acromegaly

- Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
- Polycystic liver disease (PLD)


Designed for enhanced efficacy and improved convenience for patients

CAM2029 designed to address key medical needs

- Commercially validated FluidCrystal[®] technology
- Rapid onset and long-acting octreotide release¹
- 5-fold octreotide bioavailability vs Sandostatin LAR with potential for improved efficacy¹⁻³
- State-of-the-art, pre-filled autoinjector pen enabling convenient patient self-administration
- Subcutaneous administration with thin needle (22-gauge, 12.5mm)
- Room temperature storage



Comprehensive CAM2029 clinical program



19


Positive results from ACROINNOVA 2

ACROINNOVA 2 study design

- 52-week, open-label safety study with further extension

Patient population

- New patients; uncontrolled or controlled with IGF-1<2xULN
- Patients who completed ACROINNOVA 1



ACROINNOVA 2 results


- Increased response rate from SoC baseline with in new recruited patients*
- Reinforcing long-term safety and effectiveness in ACROINNOVA 1
- Roll-over placebo patients from ACROINNOVA 1 regained IGF-1 control with CAM2029

Improved patient reported outcomes for CAM2029 vs standard-of-care baseline

- Treatment satisfaction
- Quality of life
- Dosing experience (injection)

Acromegaly symptoms decreased during treatment with CAM2029

Continued symptom improvements after switch from SoC



Acromegaly index of severity (AIS)

The AIS overall score was calculated as the sum of the scores for the 6 symptoms of headache, sweating, fatigue, joint pain, paresthesia and soft tissue swelling. The AIS overall score ranges from 0 (no symptoms) to 18 (severe symptoms)

camurus

CAM2029 progressing towards market with expected milestones 2025

AcroInnova[™]

Pivotal randomized placebo controlled and long-term safety trials in acromegaly

- Positive results from ACROINNOVA 1 and 2
- NDA acceptance in the US
 CRL for manufacturer
- Section 2025 Positive CHMP opinion in April 2025
- EC approval decision in June 2025
- NDA resubmission planned after audit of manufacturer

SORENTO[™]

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine TumOrs


- Largest randomized Phase 3 study of a SRL in GEP-NET
- SORENTO fully enrolled Q4 2023
- Target number of 194 events for primary endpoint est. early 2026



Polycystic liver Safety and efficacy TriAl with subcutaneous Octreotide

- POSITANO fully enrolled Q1 2024
- All patients completed treatment phase
- Clinical study results expected O2 2025

Towards new therapy areas





Early-stage programs

Several early-stage programs advancing

- Phase 1 study of CAM2056 ongoing
- Positive data and assessments of multiple preclinical drug candidates, including long-acting incretins


CAM2056 entered clinical development

CAM2056 – once monthly FluidCrystal semaglutide

Completed preclinical program met target profile for pharmacokinetics, pharmacodynamics (incl. weight management) and tolerability

Clinical Phase 1 study initiated

- Phase 1 study initiated assessing pharmacokinetics, pharmacodynamics (incl. weight loss), tolerability and safety of CAM2056 in overweight or obese participants who are otherwise healthy
- Top-line results expected H2 2025





Potential indications

- Type 2 diabetes
- Weight management
- Inflammation
- Neuropsychiatric
 disorders
- Substance use disorders



* Wegovy®



Camurus expanding

New headquarter in Science Village, Lund

- Opened in January 2025
- ~3,700m² on the top floors of the "The Loop"
- Offices and state-of-the-art laboratories
- Sustainability profile with LEED Gold certification
- Capacity to grow to ~250 people

Camurus AB | Rydbergs torg 4, SE-224 84 Lund, Sweden P +46 46 286 57 30 | info@camurus.com | camurus.com

Positive development expected near-term

- O Continued growth of Buvidal in Europe and Australia
- O Increased market penetration of Brixadi in the US
- Market approvals of CAM2029 in acromegaly
- O Clinical results for CAM2029 and CAM2056
- O Diversification through business development
- Positive financial outlook 2025 with expected high growth revenues (+45-61%) and profitability (+63-117%)



Thank you!

Camurus AB | Rydbergs torg 4, SE-224 84 Lund, Sweden P +46 46 286 57 30 | info@camurus.com | camurus.com camurus.